Vaccine manufacturers are facing critical challenges
End-to-end reliability of combination product component1
Cost sensitivity
Regulatory
scrutiny2
Continuity of
supply3
Optimize vaccine delivery with a glass prefilled syringe (PFS) solution
Support patient safety4
Increase efficiency of workflow4
Allow Dose-Sparing5,6
Limit hazardous waste volume5,6
A new vaccine container solution for syringe reliability and operational efficiency7,8
Introducing BD Effivax™ Glass Prefillable Syringe for Vaccines
The next generation vaccine syringe
A step forward in PFS performance as compared to previous generation BD vaccine PFS*
Designed to reduce Total Cost of Ownership (TCO)7 by minimizing line stoppage, enhancing filling and packaging performance
Access batch performance documentation, through Certificate of Analysis (CoA)
Supported by +30 regulatory experts
Supported by high production capacity for business continuity
*PFS performance refers to new and improved specifications regarding processability, cosmetics,
contamination and integrity compared to previous generation syringe, BD HypakTM for Vaccines
Explore BD Effivax™ Glass Prefillable Syringe, the new vaccine container
solution for reliability and operational efficiencies
Syringe
Integrity7
Syringe
Consistency9
Cosmetic
Quality7
In comparison to previous BD PFS vaccine technology, BD Effivax™ Glass Prefillable Syringe offers +53 new and +49 improved quality specifications out of 110 specifications.
References:
1. BD internal document. Market research, Voice of customer study. Genactis, 2018.
2. Sanduria S, Tripathy S, Murthy PN, Patra BP, Dureja H. Voicing regulatory perspectives of the combination products. J Generic Med. 2020;16(3):101-111. doi:10.1177/1741134320936724.
3. Sheryl Gay Stolberg, Sharon LaFraniere, Warning of Shortages, Researchers Look to Stretch Vaccine Supply, The New York Times, Published Jan. 5, 2021
4. Pereira CC, Bishai D. Vaccine presentation in the USA: Economics of prefilled syringes versus multidose vials for influenza vaccination. Expert Rev Vaccines. 2010;9(11):1343-1349.
5. Who - Appendix: Additional Information: Estimating Cold Chain Requirements.
6. Makwana S, Basu B, Makasana Y, Dharamsi A. Prefilled syringes: An innovation in parenteral packaging. Int J Pharm Investig. 2011 Oct;1(4):200-6. doi: 10.4103/2230-973X.93004. PMID: 23071944; PMCID: PMC3465144.)
7. BD internal references, Customer Quality Specification BD Hypak™ for Vaccine SC000110, BD Effivax™ SC000243, BD Medical – Pharmaceutical Systems Le Pont de Claix, France
8. BD internal analysis, TCO Model, BD Medical – Pharmaceutical Systems Le Pont de Claix, France
2. Sanduria S, Tripathy S, Murthy PN, Patra BP, Dureja H. Voicing regulatory perspectives of the combination products. J Generic Med. 2020;16(3):101-111. doi:10.1177/1741134320936724.
3. Sheryl Gay Stolberg, Sharon LaFraniere, Warning of Shortages, Researchers Look to Stretch Vaccine Supply, The New York Times, Published Jan. 5, 2021
4. Pereira CC, Bishai D. Vaccine presentation in the USA: Economics of prefilled syringes versus multidose vials for influenza vaccination. Expert Rev Vaccines. 2010;9(11):1343-1349.
5. Who - Appendix: Additional Information: Estimating Cold Chain Requirements.
6. Makwana S, Basu B, Makasana Y, Dharamsi A. Prefilled syringes: An innovation in parenteral packaging. Int J Pharm Investig. 2011 Oct;1(4):200-6. doi: 10.4103/2230-973X.93004. PMID: 23071944; PMCID: PMC3465144.)
7. BD internal references, Customer Quality Specification BD Hypak™ for Vaccine SC000110, BD Effivax™ SC000243, BD Medical – Pharmaceutical Systems Le Pont de Claix, France
8. BD internal analysis, TCO Model, BD Medical – Pharmaceutical Systems Le Pont de Claix, France
BD is committed to keeping your personal data protected and secure. More information on how we protect your personal data can be found in our privacy statement and our cookie policy.